Last reviewed · How we verify
methylprednisolone or budesonide
Both methylprednisolone and budesonide are corticosteroids that suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Both methylprednisolone and budesonide are corticosteroids that suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Acute exacerbations of IBD.
At a glance
| Generic name | methylprednisolone or budesonide |
|---|---|
| Also known as | Medrol, entocort, budenofalk |
| Sponsor | Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Methylprednisolone is a systemic corticosteroid with potent anti-inflammatory and immunosuppressive effects used for moderate-to-severe IBD. Budesonide is a topically-acting corticosteroid with high first-pass hepatic metabolism, allowing targeted delivery to the colon with reduced systemic exposure. Both reduce intestinal inflammation through glucocorticoid receptor activation, though budesonide offers a more favorable safety profile due to its local action and rapid metabolism.
Approved indications
- Inflammatory bowel disease (Crohn's disease and ulcerative colitis)
- Acute exacerbations of IBD
Common side effects
- Insomnia
- Headache
- Nausea
- Abdominal pain
- Hypertension (methylprednisolone)
- Adrenal suppression (with prolonged systemic use)
- Increased infection risk
Key clinical trials
- ED-Initiated School-based Asthma Medication Supervision (PHASE4)
- Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy? (PHASE4)
- 3TR Asthma Biologics Cohort (ABC) Study
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- Effects of Nasal-spraying LiveSpo Navax in Treatment of Acute Respiratory Infections in Children (NA)
- Initiation of Chronic Asthma Care Regimens in the Pediatric Emergency Department (NA)
- Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract (PHASE2)
- Adjuvant Vitamin D With Corticosteroids in Active Crohn's Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: